TNF receptor p55 and IL-8(72) and IL-8(77) isoforms: blood and urine levels in breast cancer patients.
In the preliminary study reported here, 37 patients with breast cancer and 10 healthy volunteers were analyzed for soluble TNF-R p55 and two variants of IL-8 consisting of 72 and 77 amino acid residues (IL-8(72) and IL-8(77), respectively) in their blood and urine with novel ELISA test systems. The clinical/prognostic values of determining these inflammatory cytokines at different stages of the cancer process appeared to depend on the treatment course being evaluated. In contrast to expectations, it was noted that there was a stabile tendency for decreased TNF-R p55 and IL-8(72) levels in the plasma and urine of breast cancer patients as compared with levels observed with healthy controls. Moreover, patients that underwent polychemotherapy treatments were notable for significant decreases in IL-8(72) and TNF-R p55 levels in their blood plasma; these findings contrasted with significant increases in these parameters in these patients' urine. Interestingly, the IL-8(77) isoform that now appeared both in the urine and plasma of patients was not detectable before initiation of the polychemotherapy. In spite of all these findings, individual fluctuations among these parameters still do not allow us to establish, at this time, any strong correlations between these values with any particular breast cancer stage or a type of treatment. Nonetheless, while the results here are preliminary, they demonstrate that testing for TNF-R, along with IL-8 isoforms, in the blood plasma and urine could potentially present a valid means for monitoring of the overall immune and disease progress/remission status in breast cancer patients. Ongoing studies with larger patient sample sizes, as well as collecting and analyzing samples at multiple time points--to minimize the potential influence of any inherent variability in cytokine levels in humans--will hopefully allow us to specify what these preliminary results reported here suggest, i.e., the potential utility of this experimental approach for determining disease progression or efficacy of treatment in cancer patients.
Shichkin
Valentin P
VP
Department of Immunology, Faculty of Biomedical Technologies, University "Ukraine", Kiev, Ukraine. shvp@gala.net
Lon
Anna D
AD
Yugrinova
Ludmila G
LG
Grinevich
Yury A
YA
Belova
Oksana B
OB
Berezhnaya
Ninel M
NM
Akalovich
Svetlana
S
Pashkova
Oksana
O
Voitenok
Nikolai N
NN
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000652:urine*; D005260:Female; D006801:Humans; D016209:Interleukin-8 / Q000097:blood* / Q000652:urine*; D008875:Middle Aged; D009367:Neoplasm Staging; D020033:Protein Isoforms; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000097:blood* / Q000652:urine*; D053319:Tumor Necrosis Factor Decoy Receptors / Q000097:blood* / Q000652:urine*; D016482:Urinalysis
D000970:Antineoplastic Agents; D016209:Interleukin-8; D020033:Protein Isoforms; D047888:Receptors, Tumor Necrosis Factor, Type I; D053319:Tumor Necrosis Factor Decoy Receptors; C069521:recombinant human tumor necrosis factor-binding protein-1